

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**

**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

**VOLUNTARY ANNOUNCEMENT  
PROPOSED INCREASE IN SHAREHOLDING BY CONTROLLING  
SHAREHOLDER**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company has been informed by its controlling shareholder Philip Li WANG (“**Mr. Wang**”) that, based on his recognition of the value of the Company and its confidence in the overall business development and growth potential of the Company, Mr. Wang intends to purchase additional H shares of the Company through Winning Powerful Limited (a limited company incorporated in Hong Kong and is wholly-owned by Mr. Wang) with its internal funds on the open market to increase its shareholding in the Company in about 12 months’ time commencing from the date of this announcement, with an estimated total amount up to HK\$15 million (the “**Shareholding Increasing Plan**”). Winning Powerful Limited may increase its shareholding in the Company from time to time, subject to market conditions and applicable regulatory requirements.

As at the date of this announcement, Winning Powerful Limited directly owns 45,645,584 H shares of the Company, representing approximately 18.75% of the total issued shares of the Company.

Based on the information available to the Company and to the knowledge and belief of the directors, the Company will continue to maintain a sufficient public float of the shares in issue, if the Shareholding Increasing Plan is implemented.

The board of directors of the Company considers that the Shareholding Increasing Plan of Mr. Wang demonstrates the controlling shareholder's long-term commitment to and strong confidence in the prospects of the Company.

**Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People's Republic of China, October 20, 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.*